The impact of breathing motion versus heterogeneity effects in lung cancer treatment planning by Rosu, Mihaela et al.
The impact of breathing motion versus heterogeneity effects
in lung cancer treatment planning
Mihaela Rosu
Department of Radiation Oncology, The University of Michigan, Ann Arbor, Michigan 48109-0010
Indrin J. Chetty
Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska 68198-7521
Daniel S. Tatro and Randall K. Ten Haken
Department of Radiation Oncology, The University of Michigan, Ann Arbor, Michigan 48109-0010
Received 4 December 2006; revised 30 January 2007; accepted for publication 13 February 2007;
published 23 March 2007
The purpose of this study is to investigate the effects of tissue heterogeneity and breathing-induced
motion/deformation on conformal treatment planning for pulmonary tumors and to compare the
magnitude and the clinical importance of changes induced by these effects. Treatment planning
scans were acquired at normal exhale/inhale breathing states for fifteen patients. The internal target
volume ITV was defined as the union of exhale and inhale gross tumor volumes uniformly
expanded by 5 mm. Anterior/posterior opposed beams AP/PA and three-dimensional 3D-
conformal plans were designed using the unit-density exhale “static” dataset. These plans were
further used to calculate a density-corrected “heterogeneous” static dose and b heterogeneous
cumulative dose, including breathing deformations. The DPM Monte Carlo code was used for dose
computations. For larger than coin-sized tumors, relative to unit-density plans, tumor and lung
doses increased in the heterogeneity-corrected plans. In comparing cumulative and static plans,
larger normal tissue complication probability changes were observed for tumors with larger motion
amplitudes and uncompensated breathing-induced hot/cold spots in lung. Accounting for tissue
heterogeneity resulted in average increases of 9% and 7% in mean lung dose MLD for the 6 MV
and 15 MV photon beams, respectively. Breathing-induced effects resulted in approximately 1%
and 2% average decreases in MLD from the static value, for the 6 and 15 MV photon beams,
respectively. The magnitude of these effects was not found to correlate with the treatment plan
technique, i.e., AP/PA versus 3D-CRT. Given a properly designed ITV, tissue heterogeneity effects
are likely to have a larger clinical significance on tumor and normal lung treatment evaluation
metrics than four-dimensional respiratory-induced changes. © 2007 American Association of
Physicists in Medicine.
DOI: 10.1118/1.2713427
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Radiation therapy is one of the principal treatment options
for medically inoperable lung tumors. However, even with
significant advances in the delivery of radiation, 5-y survival
rates remain poor for patients with advanced stage disease.1–5
As such, research efforts have been devoted toward individu-
alizing the radiation therapy process to each patient’s specific
anatomy and physiology in the planning and the delivery of
high dose conformal therapy. These efforts have been en-
couraged by studies that indicate that higher doses can be
safely delivered to limited lung volumes,6–14 as well as the
fact that higher target doses relate to improved tumor
control.15–18 It should, however, be kept in mind that these
results may carry some bias and limitations. This is attributed
to the fact that the doses quoted in trials are usually calcu-
lated using no or limited heterogeneity correction algorithms.
Additionally, changes in dose due to organ motion and
1462 Med. Phys. 34 „4…, April 2007 0094-2405/2007/34„4…/deformation are not generally accounted for in dose evalua-
tion. As we move toward individualization in the treatment
planning process using advanced methods, such as four-
dimensional 4D imaging, it becomes critical that we incor-
porate methods to correctly accumulate these doses using the
patient CT-based densities, ultimately to more accurately as-
sess the dose actually delivered to the patient.
To better estimate doses in anatomies with heterogeneous
tissue densities, such as the lung, accurate dose calculation
engines have been developed. In this regard, Monte Carlo
based dose calculation algorithms are believed to be the most
accurate.19–29 They can provide dose calculations that prop-
erly account for patient-specific physical descriptions of
anatomy including electron density and atomic number in-
formation, and for the charged particle transport processes
that are influenced by different tissue properties. However,
although many studies have demonstrated that significant er-
rors are present when homogeneous media is assumed where
heterogeneities are actually present see AAPM Report No.
14621462/12/$23.00 © 2007 Am. Assoc. Phys. Med.
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debated whether or not heterogeneity corrections should be
used.31–37
Breathing motions and the distortions associated with
them triggered the development of sophisticated CT systems
that allow the acquisition of time-dependent images that ex-
tend across the entire breathing cycle, setting the basis for
what is nowadays termed as 4D radiation therapy.38 Of
course, much more work is warranted before many of the
uncertainties introduced by the additional components in-
volved in a 4D therapy process e.g., image registration, data
sorting, inter- and intra-fraction breathing variability, to
name a few are fully understood and quantified. Even if a
4D radiotherapy treatment could be assumed to be error free,
the benefits of using a technology that demands such large
resource utilization are yet to be proven, and the classes of
patients that could make best use of these advances are yet to
be identified.
The present study compares the dosimetric effects of het-
erogeneous media versus breathing-induced motion and de-
formation for patients with lung tumors treated with confor-
mal radiotherapy. The comparison was performed by
assessing the impact of heterogeneities and breathing motion
on clinically relevant target and normal tissue treatment
evaluators such as equivalent uniform dose EUD, normal
tissue complication probability NTCP, and mean lung dose
MLD. A secondary goal of the study was to identify sce-
narios were heterogeneities or respiratory induced motion
were more likely to have a clinically important effect, with
emphasis on the analysis of motion/deformation effects, an
area that has not been extensively investigated in the litera-
TABLE I. Patient information regarding tumor locatio
treatment plans UR  upper right lobe, UL  upper
 lower left lobe. The breathing motion amplitude w
ment between exhale and inhale.
Patient
Tumor
location
GTV
size
cm3
Breath
moti
ampli
cm
1 MR 67 1.2
2 UR 300 0.9
3 LR 23 1.1
4 LR 160 1.7
5 UR 816 0.1
6 UR 103 0.5
7 UR 29 0.6
8 UL 5 0.1
9 UL 82 1.0
10 ML 560 0.7
11 MR 17 0.6
12 UL 89 1.6
13 LR 490 0.8
14 MR 192 2.1
15 UR 50 1.4ture.
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A. Patient data
Fifteen patients with unresectable lung tumors were in-
volved in this study under a protocol approved by the Inter-
nal Review Board at the University of Michigan Health Sys-
tems. These patients had various tumor sizes, locations, and
motion amplitudes Table I. Exhale and inhale scans ac-
quired at normal breath-hold during the same session were
available for all patients.
B. Treatment planning
For each patient, the exhale and inhale gross tumor vol-
umes GTVs were contoured by a physician, and uniformly
expanded 0.5 cm to form clinical tumor volumes CTVs. An
internal target volume ITV was then defined as the union of
the exhale and inhale CTVs. In this study we assumed that
a the setup errors were dealt with prior to radiation delivery
and b the breathing motion can be described by the as-
sumed model,39 with no inter- or intra-fraction variations.
That is, all other factors that would normally lead to further
expansion of the ITV to form a planning target volume were
not considered here in order to isolate the breathing motion
and tissue density effects, and their relative magnitudes.
Critical organs spinal cord, esophagus, heart, lungs were
also contoured within the treatment planning system.
Each patient was planned with an anterior/posterior op-
posed beams plan AP/PA plan and with a three-
dimensional 3D-conformal plan multiple coplanar beams
and segments using 6 MV photon beams. The intent here
ze, motion amplitude, and prescription doses for all
obe, MR  medial right, LR  lower right lobe, LL
rived from the center-of-mass of the tumor displace-
Prescription dose Gy
6 MV 15 MV
AP/PA
3D
conformal
3D
conformal
42 84 84
48 72 76
100 100 100
100 100 100
48 60 -
50 52 -
100 100 -
100 100 -
48 74 -
66 60 -
100 100 -
100 100 -
46 100 -
54 70 -
48 100 -n, si
left l
as de
ing
on
tude
was to investigate whether the heterogeneity and motion ef-
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plans were designed on the exhale static, planning dataset,
assuming unit density. For four patients that had larger mo-
tion amplitudes 3D-conformal plans using 15 MV photon
beams were designed as well, again using the exhale dataset
and assuming unit density. The number of beams and seg-
ments for the 3D-conformal plans ranged between 5 and 11.
The prescription doses for each scenario are summarized in
Table I.
The dose distributions were calculated using the DPM
Monte Carlo code,26 which has been integrated within the
UMPlan in-house treatment planning system.40 The electron
step size was 2 mm, and the low energy electron and photon
cutoff kinetic energies were 200 and 50 keV, respectively.
1.5109 histories were simulated per plan, resulting in 1-
statistics of better than 0.5% on average within the target.41
The plans calculated using the exhale homogeneous dataset
were normalized to 100% at the isocenter. All the other plans
were normalized to the isocenter dose from the reference
exhale homogeneous dose distribution to illustrate dose
changes for the same number of monitor units per beam as in
the reference exhale plan. The dose grid size in all dimen-
sions was 3.5 mm.42
The plans were optimized to cover the ITV with 100±5%
of the assigned prescription dose Table I while keeping the
critical normal tissues below tolerances:6,13,18 the spinal cord
must remain below a dose equivalent to 50 Gy in 2 Gy frac-
tions; the esophagus effective volume Veff Ref. 43 com-
puted with a normalization dose equivalent to 72 Gy in 2 Gy
fractions must be less than 1/3 of the organ volume; the heart
Veff computed with normalization doses equivalent to 40 Gy
and 65 Gy in 2 Gy fractions must be less than 1 and 1/3 of
the organ volume, respectively; the normal lung Veff normal-
ized to the prescription dose must be less than 0.4, and is
used to determine the assigned dose12,13,18 to be consistent
with the 15% target iso-NTCP of grade 3 or higher radiation
pneumonitis model43,44 model parameters were45 TD50
=30.8 Gy, m=0.99, n=0.37. If any of these tolerance doses
could not be met, the dose was adjusted until the critical
structure dose was not exceeded.
Each plan designed on the exhale homogeneous dataset
beam weights and monitor units was also used for the cal-
culation of the heterogeneous dose distribution. For evaluat-
ing the inhomogeneity effects on tumors and normal lung
doses for each patient, the homogeneous and the heteroge-
neous exhale dose distributions were compared Scenario 1.
Each reference static exhale plan beam weights and
monitor units was also used for heterogeneity-corrected
dose computation on the inhale dataset. The inhale dose dis-
tribution was then mapped back onto the exhale dataset using
the transformation provided by a deformable B-spline regis-
tration technique.46 A time-weighted summation of the ex-
hale and inhale doses was used to estimate the cumulative
heterogeneous dose that would be received by a patient dur-
ing free breathing radiation delivery.42,47 The weighting co-
efficients used were 70% for exhale and 30% for inhale, as
derived from a breathing probability function assumed for all
Medical Physics, Vol. 34, No. 4, April 2007patients for planning.39 The comparison between the cumu-
lative and exhale heterogeneous dose distributions Scenario
2 provided information regarding the breathing-induced mo-
tion effects. We also assessed the cumulative effect of het-
erogeneity and motion effects by comparing the heteroge-
neous cumulative and the homogeneous static dose
distributions Scenario 3. All three scenarios are depicted in
Fig. 1.
C. Heterogeneity and breathing-induced motion and
deformation assessment
The effects of heterogeneity and/or breathing-induced
motion and deformation were assessed qualitatively, through
dose difference displays, and quantitatively, thorough treat-
ment metrics commonly used in lung cancer treatment plan-
ning: CTV EUD,48 MLD, and NTCP. These metrics were
evaluated for the anatomical structures segmented on the ex-
hale dataset. The changes in isocenter doses from the exhale
homogeneous values were also investigated. The clinical sig-
nificance of the changes induced by inhomogeneities and/or
motion was determined based on previous work at our
institution:49,50 for the tumor, the change in tumor dose is
clinically important if it equals or exceeds a treatment frac-
tion size e.g., 2 Gy; for the normal lung tissue, the change
in lung NTCP for a given dose distribution from a reference
dose distribution is clinically important if a change in the
prescription dose of at least one treatment fraction is needed
in order to achieve the same complication probability level
from the reference dose distribution iso-NTCP based dose
prescription.
III. RESULTS
A. Image registration assessment
Registration is an important step in the computation of
cumulative doses from multiple datasets. The accuracy of the
process is usually described by the accuracy of bringing into
alignment anatomical landmarks and was found to be about
2–3 mm, on average, for the patient population involved in
this study. The visual inspection of the overlapped exhale
and the deformed inhale datasets inhale CT scans distorted
to the exhale state was also used to validate the registration
quality and was found to be acceptable for all cases one
example is provided in Fig. 2.
B. Heterogeneity effects
Shown in Fig. 3 are several dose difference displays be-
tween heterogeneous and homogeneous dose distributions. In
general, the heterogeneous dose calculation predicts higher
doses than the homogeneous dose calculation for both tu-
mors and lungs, as indicated by the hot spots. However, cold
spots arise near interfaces and at the beam edges. The het-
erogeneity effects on CTV EUD, and the prescription dose
changes required in the heterogeneous dose calculation to
restore the lung NTCP from the homogeneous calculation are
illustrated in Figs. 4 and 5 dark-gray bars.
bine
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EUD over 8 Gy were found for Patient 3 6 MV, AP/PA
plan; Fig. 3a and Patient 1 6 MV, conformal plan; Fig.
3d, whereas the smallest increase was observed for Patient
5 6 MV, AP/PA plan; Fig. 3b. Decreases of about 2 Gy in
the heterogeneous EUD were observed for Patient 8 6 MV,
conformal plan; Fig. 3e and Patient 3 15 MV, conformal
plan; Fig. 3f.
In the heterogeneous calculation, the correction factors for
the isocenter doses i.e., the ratio of isocenter doses in the
FIG. 1. A treatment plan is designed on the exhale dataset, assuming hom
calculation on the exhale and inhale datasets. The heterogeneous inhale dose
the exhale 70% and inhale 30% doses estimates the cumulative dose to b
The comparison between exhale homogeneous and heterogeneous doses illu
and cumulative heterogeneous dose illustrates the effects induced by breath
exhale homogeneous and cumulative heterogeneous doses illustrates the com
FIG. 2. B-spline deformable registration between the exhale and inhale
datasets for Patient 14 for an example coronal cut. All cuts exhale, inhale,
deformed inhale are displayed for the same plane in the treatment room
coordinate system. The bottom row illustrates the intensity difference map
between exhale and inhale images before registration, as well as between
exhale and deformed inhale images after registration; the light-colored
regions indicate misalignments.
Medical Physics, Vol. 34, No. 4, April 2007heterogeneous versus the homogeneous plans, averaged
1.046 range: 1–1.16 for the AP/PA 6-MV plans, 1.035
range: 0.996–1.11 for the conformal 6 MV plans, and
1.042 range: 1.02–1.08 for the conformal 15 MV plans.
eous media =1 g/cm3. The plan is also used for heterogeneous dose
ibution is scored back onto the exhale dataset and the time weighted sum of
eived by a patient during free breathing delivery of the radiation treatment.
s the inhomogeneity effects Scenario 1. The comparison between exhale
duced motion and deformation Scenario 2. The comparison between the
d effect of motion and inhomogeneities.
FIG. 3. Dose difference displays between heterogeneous and homogeneous
dose distributions computed on the exhale dataset for several patients. The
hot/cold spots indicate regions were the heterogeneous dose distribution
predicts larger/smaller values than the homogeneous dose distribution. The
arrows indicate cold spots near interfaces in the heterogeneous dose calcu-
lation. The numbers indicate percent dose differences relative to the pre-ogen
distr
e rec
strate
ing-inscription dose.
1466 Rosu et al.: Motion versus heterogeneity effects in lung cancer treatment 1466FIG. 4. Tumor EUD Gy changes from their homogeneous exhale values as a result of heterogeneity dark gray bars, motion/deformation black bars, and
the combined effect of motion and heterogeneity light gray bars. The dark horizontal lines ±2 Gy correspond to the treatment fraction size assumed for the
patients from this study.Medical Physics, Vol. 34, No. 4, April 2007
1467 Rosu et al.: Motion versus heterogeneity effects in lung cancer treatment 1467FIG. 5. Changes in the prescription dose from the homogeneous exhale value required in an iso-NTCP protocol when heterogeneities dark gray bars,
motion/deformation black bars, and the combined effect of motion and heterogeneity light gray bars are included in dose calculations. The dark horizontal
lines ±2 Gy correspond to the treatment fraction size assumed for the patients from this study.Medical Physics, Vol. 34, No. 4, April 2007
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heterogeneous calculations predicted larger doses than the
corresponding homogeneous calculations. The decrease in
the prescription dose that would be required in the heteroge-
neous dose calculation in order to achieve the complication
probability level estimated in the homogeneous dose calcu-
lation illustrated in Fig. 5 was at least one treatment frac-
tion in all cases. The largest changes were 16 Gy 8 frac-
tions for Patient 11 6 MV, AP/PA plan; Fig. 3c and
14 Gy 7 fractions for Patient 3 6 MV, AP/PA and con-
formal plans; Figs. 3a and 3f.
Shown in Fig. 6 are scatter plots of the homogeneous
versus the heterogeneous MLDs for the 6 MV and the
15 MV beams. For the patients involved in this study, the
average change in the heterogeneous MLD from the homo-
geneous value, as predicted by the linear fit through origin
from Fig. 6, indicates an increase of 9% for the 6 MV pho-
tons range: 5%–16%, and 7% for the 15 MV beam range:
6%–11%. The 6 MV data from the plot include the AP/PA
and the conformal plan MLDs. The average scaling factors
between the heterogeneous and the homogeneous MLDs was
not shown to correlate with the dose distribution conformal-
ity.
C. Breathing-induced motion and deformation effects
Figure 7 displays dose difference maps between heteroge-
neous cumulative and heterogeneous static dose distribu-
tions. Breathing redistributes doses, creating hot and cold
spots in the cumulative dose. The motion-induced effects on
tumor EUD, and the prescription dose changes required in
the cumulative dose distribution to restore the static lung
NTCP are illustrated in Figs. 4 and 5 black bars.
A slight decrease in tumor coverage was observed in most
cases, except for Patient 4 all plans and Patient 1 6 and
15 MV conformal plans. The isocenter doses for the cumu-
lative distributions were virtually unchanged from their static
values.
The normal tissue doses increased, decreased, or re-
mained unchanged, depending on the breathing amplitude
and the tumor location. The comparison between static and
cumulative normal lung doses indicates that changes in the
prescription dose in an iso-NTCP based dose escalation pro-
tocol is required in some cases. The largest changes relative
to the static dose distributions were observed as follows:
6 Gy 3 fractions decrease for Patient 4 6 MV, AP/PA
plan and Patient 9 6 MV, conformal plan; 4 Gy 2 frac-
tions increase for Patient 2 15 MV, conformal plan; Fig.
7b; 4 Gy 2 fractions decrease for Patient 4 6 MV,
conformal plan; Fig. 7d and 15 MV, conformal plan, and
Patient 9 6 MV, AP/PA plan; Fig. 7f. For the patients
involved in this study, the average change in the cumulative
heterogeneous dose MLD relative to the static heterogeneous
dose, as predicted by the linear fit through the origin shown
in Fig. 6, indicates 1% decrease for the 6 MV beam
range: −4% –10% and 2% decrease for the15 MV beam
range: −5–5%. The 6 MV data from the plot include the
AP/PA and the conformal plan MLDs. The average scaling
Medical Physics, Vol. 34, No. 4, April 2007factors between the cumulative and the static MLDs were
found not to correlate with the dose distribution conformal-
ity.
D. Heterogeneity versus breathing-induced motion
and deformation effects
The combined effect of heterogeneity and breathing-
induced motion on tumor and normal lung doses, compared
with a scenario in which neither one of these effects is ac-
counted for, is illustrated in Figs. 4 and 5 light gray bars. It
can be noticed that heterogeneity effects have the largest
contribution toward an accurate estimation of the target cov-
erage in all cases investigated here. For some patients Pa-
tients 2, 4, 9, 10, and 14, however, large breathing-induced
excursions resulted in hot or cold spots that were not neces-
sarily simultaneously present in the normal lung tissue. The
lack of this compensatory effect between hot and cold spots
posed a more significant effect on volume effect indices for
these patients.
The magnitude of the changes in dose as a result of mo-
tion or heterogeneity was not a representative indicator of
the effects of motion on lung treatment evaluators. For Pa-
tient 14 Fig. 8, for example, the magnitude of the dosimet-
ric differences induced by the respiratory motion is more
than twice the magnitude of the differences induced by het-
erogeneity, although the impact on MLD/NTCP clearly fa-
vors the heterogeneity effects. With the exception of Patient
9 Fig. 8, the effects of motion on lung treatment metrics,
even when significant, were usually smaller than the hetero-
geneity induced effects.
The isocenter dose changes in the heterogeneous cumula-
tive distributions from the homogeneous static values were
the same as those indicated by the heterogeneous static cal-
culation. The corresponding correlation coefficients between
MLDs 8% and 5% for 6 and 15 MV beams, respectively
were consistent with the cumulative value of the changes
generated independently by heterogeneity and motion.
IV. DISCUSSION
A. Heterogeneity effects
The increased doses predicted by the heterogeneous dose
calculations are a consequence of the reduced attenuation of
the primary beam in lung tissue. The effect is generally more
pronounced as the amount of lung tissue traversed by the
beam becomes larger. For the cases represented in Figs. 3a
and 3d that had the largest increase in the heterogeneous
CTV EUD, the ratios between the physical and the radiologi-
cal path lengths were, on average over all beams, 2.1 and
1.3, respectively. On the other hand, for the case from Fig.
3b where the increase in EUD was minimal, the physical
and radiological path lengths were almost equal. The physi-
cal to radiological path length ratios were fairly large for
cases from Figs. 3e and 3f as well 1.3 and 1.2, respec-
tively. However, a decrease in EUD was found in the het-
erogeneous calculations for these coin-sized lesions because
the range of the electrons in the lung tissue becomes larger
1469 Rosu et al.: Motion versus heterogeneity effects in lung cancer treatment 1469than the field size resulting in a loss of charged particle
equilibrium.51,52 Indeed, Patient 8 Fig. 3e had a 5 cm3
GTV volume, corresponding to a radius of about 1 cm, com-
parable with the 1 cm electron range in water for a 6 MV
Medical Physics, Vol. 34, No. 4, April 2007photon beam, whereas for Patient 3 Fig. 3f the GTV vol-
ume was 23 cm3, corresponding to a radius of about 1.8 cm,
smaller than the 2.5 cm electron range in water for a
FIG. 6. Scattered plots illustrating the
correlations between homogeneous/
cumulative and heterogeneous/static
dose distributions for the 6 MV and
15 MV beam energies.15 MV photon beam.
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even when prescription doses are similar. Patients 3 and 7,
for example, had similar target volumes 23 and 29 cm3, re-
spectively, and both were prescribed 100 Gy in the homo-
geneous AP/PA plans. The heterogeneous EUD, however,
was about 8 Gy larger for Patient 3—a consequence of the
larger beam path length through lung in the case of Patient 3
2.1 versus 1.3 average physical to radiological path length
ratios.
On average, the heterogeneity increased the isocenter
dose. The magnitude of the effect is somewhat different for
different beam energies and beam arrangements, with a trend
FIG. 7. Dose difference displays between cumulative and static exhale
dose distributions reported on the exhale dataset for several patients. The
color code is the same as in Fig. 3. The white arrows indicate hot and cold
spots created by motion and deformation. In addition, the motion amplitude
cm and the direction along which the tumor has the largest component are
indicated. Also shown are maximum and/or minimum point dose differences
inside the normal lung tissue. The numbers indicate percent dose differences
relative to the prescription dose.
FIG. 8. Difference maps between dose distributions corresponding to the
three scenarios investigated in this study, for example, axial, coronal, and
sagittal cuts, for Patients 9 and 14. The color code is the same as in Fig. 3.
The numbers indicate the maximum and/or minimum point dose differences
inside the normal lung tissue.
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when multiple beams are used, as indicated by the range of
values recorded. Occasionally, a slight decrease in the iso-
center heterogeneous dose was observed, owing to larger
beam path lengths through bony structures sternum and ver-
tebral bodies. The results presented in this study are ex-
pected and are similar to those previously reported by
others.31,32,34 The values reported here are, however, slightly
larger mainly due to patient selection. For example, if more
patients with mediastinal tumors were included, the changes
in isocenter dose would be reduced especially for the AP/PA
beam technique.
The effect of heterogeneities on the prediction of the
radiation-induced pneumonitis is still controversial. Mah and
van Dyk,31 for example, predicted an increased risk of lung
toxicity when homogeneous media was assumed for dose
prescription without a corresponding change in the prescrip-
tion dose, whereas Chang et al.37 suggested that the homo-
geneous and heterogeneous dosimetric parameters are highly
correlated, and therefore the pulmonary toxicity data from
the existing literature are valid for both homogeneous and
heterogeneous plans. The 9% average increase in MLD for
the 6 MV beam from our study is in very good agreement
with the data from the first study mentioned above, but dif-
fers from the 4% average MLD increase reported in the sec-
ond study. As we have found that the average change in
MLD is not affected by the plan conformality, we can only
speculate that the discrepancy between our study and the
study by Chang et al.37 is due to the patient selection and
possibly the dose calculation algorithm used to correct for
heterogeneities.
B. Breathing-induced motion and deformation effects
The minimal changes in CTV EUD and isocenter doses in
face of motion are a consequence of an appropriate target
design ITV based on the union of exhale and inhale GTVs
in this study. In addition, the motion-induced effects affect
the penumbral regions, where high dose gradients exist over
the range of motion, and thus they are unlikely to alter iso-
center doses when the isocenter is located inside the target.
Small EUD increases were found in several cases, and they
were due to motion-induced hot spots that occurred at the
edge of some beam segments that intersected the target.
The hot/cold spots seen in the dose difference maps from
Fig. 7 are created in regions that move in/out of the radiation
field during breathing. Of importance in the redistribution of
the cumulative doses is how these hot and cold spots are
located with respect to the normal lung tissue, as previously
reported in a study involving intrahepatic lesions.53 Here one
is presented with one of the two scenarios: a either the hot
or the cold spot falls into the normal lung tissue, as illus-
trated in Figs. 7b and 7d–7f; or b both the hot and the
cold spots fall into the normal lung in either one of the
lungs, as in Fig. 7c, or in both lungs, as in Fig. 7a. As
lungs are parallel organs, for which the response to radiation
is correlated with the mean dose received, one can easily
anticipate that when both the hot and the cold spots occur
1471 Rosu et al.: Motion versus heterogeneity effects in lung cancer treatment 1471inside the lung they tend to offset each other, leaving the
mean overall toxicity virtually unchanged, regardless of the
motion amplitude. Patient 14, for example, underwent the
largest tumor motion amplitude 2.1 cm, and yet, the change
in normal lung toxicity was barely enough to allow for a
fraction increase in the prescription dose in the conformal
plan. By contrast, when either a hot or a cold motion induced
spot occurred inside the lung, the overall lung toxicity
increased/decreased compared to the corresponding static
value. However, since the lungs are relative large-volume
organs, the respective hot or cold spot would need to encom-
pass a rather large portion on the normal tissue in order to
have a measurable effect on the overall mean lung dose. This
suggests that rather large motion amplitudes are required to
create clinically significant changes in the mean lung dose.
Small motion amplitudes are unlikely to lead to important
changes, even when an uncompensated hot or cold spot ex-
ists Fig. 7e.
In general, with respect to the cranio-caudal direction of
motion, in this limited study the MLD is observed to: in-
crease if the tumor is located near the diaphragm moving
inferiorly or at the apex moving superiorly, decrease for
apical tumors moving inferiorly, and remain almost un-
changed otherwise. It should also be noted that cranio-caudal
motion components were usually larger and more likely to
influence the redistribution of doses, as they generally occur
perpendicular to the beam axis for axial beams. Similarly,
the lateral motion component can be expected to influence
dose distributions in AP/PA beam settings; however, the mo-
tion amplitude along this direction is usually small.
An interesting finding of the motion component of this
study is the overall decrease albeit by a small amount in the
cumulative dose distribution MLD, when the entire popula-
tion of patients was considered. Short of those cases where
an uncompensated hot spot existed, the reduction of lung
dose indicates, in fact, that lungs do not expand isotropically:
the lower regions tend to undergo more motion and deforma-
tion relative to the upper regions. The overall result is that
the MLD change is more driven by the cold spots thereby
resulting in a slight decrease in the MLD.
The motion effects appear to be somewhat more pro-
nounced for the higher beam energy, due to wider penumbra,
especially inside the low-density lung tissue. However, the
differences are rather small.
C. Heterogeneity versus breathing-induced motion
and deformation effects
Not accounting for motion/deformation does not intro-
duce significant errors in the target coverage assessment, a
natural consequence of an appropriate planning margin. The
margin expansion, however, cannot and is not intended to
protect against the heterogeneity effects.
For the normal lung tissue, the heterogeneity effects alone
are not sufficient to accurately evaluate doses when uncom-
pensated hot or cold spots are created inside the lung as a
result of large tumor excursions.
Medical Physics, Vol. 34, No. 4, April 2007The magnitude of the dosimetric changes induced by mo-
tion at a point in space should not be associated with its
influence on treatment metrics, as demonstrated by the ex-
ample from Fig. 8 Patient 14. There are two main causes
for discrepancies between the magnitudes of the point dose
changes and how these dosimetric changes affect lung
NTCPs and MLDs. First, the motion-induced changes occur
in smaller regions around beam edges. In contrast, heteroge-
neity effects are present everywhere inside the radiation
field, and therefore, they will have a greater weight in the
overall lung dose change. Second, in those cases where the
hot and the cold spots occur inside the lung, their contribu-
tions offset each other, at least in part, thus decreasing their
combined contribution to the overall lung dose.
The discrepancies between the heterogeneity and motion-
induced effects on normal lung tend to be smaller at higher
beam energies, as suggested by the correction factors derived
from the linear fits illustrated in Fig. 6. This is a consequence
of decreased heterogeneity effects, rather than a significant
change in the magnitude of motion-induced effects with
changing beam energy.
In this study, the heterogeneity effects were assessed only
for the exhale dataset. Due to the reduced lung density dur-
ing inhalation, the exhale dose usually overestimates the
dose received by the lung tissue during any other phase of
the breathing cycle, with the largest discrepancy occurring at
inhale. The same applies to tumors larger than coin size, for
reasons related to decreased attenuation, as discussed previ-
ously. However, although there is a range of lung densities
between inhalation and exhalation 0.16 to 0.35 g/cm3,54
these values are different from the unit density assumed in
homogeneous calculation in the first place. Therefore, the
relative importance of the heterogeneity effects vs. motion
effects is not expected to change significantly when inhale
geometries are considered.
For the assessment of the motion/deformation effects,
only the extreme patient geometries were included, based on
a previous study47 indicating that cumulative doses can be
estimated within 2%–3% accuracy when only the exhale and
the inhale datasets are used. As such, the relative effects of
motion and heterogeneity are expected to be quite robust,
regardless of the number of breathing phases used for the
cumulative dose reconstruction. In addition, the assumptions
made in this study regarding the shape and the reproducibil-
ity of the breathing pattern are also expected to have minor
influence on the relative comparison between heterogeneity
and motion induced effects, as the effect of breathing vari-
ability on the cumulative dose is small, unless systematic
deviations in the respiratory pattern during radiation delivery
from the assumed planning model occur.47,50
The results of this study suggest that although large point
dose changes are induced by both the lack of heterogeneity
and motion/deformation corrections, tissue heterogeneity ef-
fects are likely to have a larger significance in terms of pre-
dicted clinical response parameters for tumor and normal
lung given a properly designed ITV. This may indicate the
1472 Rosu et al.: Motion versus heterogeneity effects in lung cancer treatment 1472area of greater impact for investigations into dose calcula-
tions for lung tumor irradiations and quality assurance of
treatment planning systems.
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